Preclinical assessment of mutant human TRIM5α as an Anti-HIV-1 transgene

Human Gene Therapy

Volumn 26, Issue 10, 2015, Pages 664-679

  Jung, Ulrike ^a   Urak, Kevin ^a   Veillette, Maxime ^b   Nepveu Traversy, Marie Édith ^b   Pham, Quang Toan ^b   Hamel, Sophie ^b   Rossi, John J ^a   Berthoux, Lionel ^b,c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^c City of Hope National Medical Center ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENTIVIRUS VECTOR; TRANSCRIPTION FACTOR JUNB; TRIPARTITE MOTIF PROTEIN 5; TUMOR NECROSIS FACTOR ALPHA; CARRIER PROTEIN; MUTANT PROTEIN; PROTEIN BINDING; TRIM5 PROTEIN, HUMAN;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; LYMPHOCYTE; MUTANT; NONHUMAN; PROTEIN EXPRESSION; RHESUS MONKEY; STABLE EXPRESSION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; GENE THERAPY; GENETICS; HIV INFECTIONS; LENTIVIRINAE; MUTATION; PATHOGENICITY; PATHOLOGY; VIROLOGY;

ANIMALS; CARRIER PROTEINS; GENETIC THERAPY; HIV INFECTIONS; HIV-1; HUMANS; LENTIVIRUS; LYMPHOCYTES; MACACA MULATTA; MUTANT PROTEINS; MUTATION; PROTEIN BINDING; TRANSGENES;

EID: 84945573328     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.059     Document Type: Article

References (107)

1. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zincfinger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28: 839-847
2. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014; 370: 901-910
3. Chung J, Rossi JJ, Jung U. Current progress and challenges in HIV gene therapy. Future Virol 2011; 6: 1319-1328
4. Esbjornsson J, Mansson F, Martinez-Arias W, et al. Frequent CXCR4 tropism of HIV-1 subtype a and CRF02-AG during late-stage disease-indication of an evolving epidemic in West Africa. Retrovirology 2010; 7: 23
5. Stremlau M, Owens CM, Perron MJ, et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427: 848-853
6. Owens CM, Yang PC, Gottlinger H, et al. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J Virol 2003; 77: 726-731
7. Cowan S, Hatziioannou T, Cunningham T, et al. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci USA 2002; 99: 11914-11919
8. Forshey BM, Shi J, Aiken C. Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J Virol 2005; 79: 869-875
9. Ikeda Y, Ylinen LM, Kahar-Bador M, et al. Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J Virol 2004; 78: 11816-11822
10. Shi J, Aiken C. Saturation of TRIM5 alpha-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. Virology 2006; 350: 493-500
11. Stremlau M, Perron M, Lee M, et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA 2006; 103: 5514-5519
12. Perez-Caballero D, Hatziioannou T, Zhang F, et al. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol 2005; 79: 15567-15572
13. Campbell EM, Perez O, Anderson JL, et al. Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol 2008; 180: 549-561
14. Black LR, Aiken C. TRIM5alpha disrupts the structure of assembled HIV-1 capsid complexes in vitro. J Virol 2010; 84: 6564-6569
15. Perron MJ, Stremlau M, Lee M, et al. The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-Tropic murine leukemia virus capsid. J Virol 2007; 81: 2138-2148
16. Zhao G, Ke D, Vu T, et al. Rhesus TRIM5a disrupts the HIV-1 capsid at the inter-hexamer interfaces. PLoS Pathog 2011; 7: e1002009
17. Anderson JL, Campbell EM, Wu X, et al. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J Virol 2006; 80: 9754-9760
18. Diaz-Griffero F, Li X, Javanbakht H, et al. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 2006; 349: 300-315
19. Rold CJ, Aiken C. Proteasomal degradation of TRIM5alpha during retrovirus restriction. PLoS Pathog 2008; 4: e1000074
20. Berthoux L, Sebastian S, Sokolskaja E, et al. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J Virol 2004; 78: 11739-11750
21. Pertel T, Hausmann S, Morger D, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011; 472: 361-365
22. Tareen SU, Emerman M. TRIM5 takes on pattern recognition. Cell Host Microbe 2011; 9: 349-350
23. Pham QT, Bouchard A, Grutter MG, et al. Generation of human TRIM5alpha mutants with high HIV-1 restriction activity. Gene Ther 2010; 17: 859-871
24. Yap MW, Nisole S, Lynch C, et al. TRIM5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA 2004; 101: 10786-10791
25. Berthoux L, Sebastian S, Sayah DM, et al. Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues. J Virol 2005; 79: 7883-7888
26. Anderson J, Akkina R. TRIM5alpha(rh) expression restricts HIV-1 infection in lentiviral vectortransduced CD34( + )-cell-derived macrophages. Mol Ther 2005; 12: 687-696
27. Kambal A, Mitchell G, Cary W, et al. Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Mol Ther 2011; 19: 584-593
28. Yap MW, Nisole S, Stoye JP. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 2005; 15: 73-78
29. Pham QT, Veillette M, Brandariz-Nunez A, et al. A novel aminoacid determinant of HIV-1 restriction in the TRIM5a variable 1 region isolated in a random mutagenic screen. Virus Res 2013; 173: 306-314
30. Li Y, Li X, Stremlau M, et al. Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. J Virol 2006; 80: 6738-6744
31. Veillette M, Bichel K, Pawlica P, et al. The V86m mutation in HIV-1 capsid confers resistance to TRIM5a by abrogation of cyclophilin A-dependent restriction and enhancement of viral nuclear import. Retrovirology 2013; 10: 25
32. Lamers CH, Willemsen R, Van Elzakker P, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011; 117: 72-82
33. Tripathy SK, Black HB, Goldwasser E, et al. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545-550
34. Yin Y, Takahashi Y, Ebisuura N, et al. Removal of transgene-expressing cells by a specific immune response induced by sustained transgene expression. J Gene Med 2014; 16: 97-106
35. Troyer RM, Mcnevin J, Liu Y, et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 2009; 5: e1000365
36. Friedrich TC, Dodds EJ, Yant LJ, et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 2004; 10: 275-281
37. Liu Y, Mcnevin J, Zhao H, et al. Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol 2007; 81: 12179-12188
38. Martinez-Picado J, Prado JG, Fry EE, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80: 3617-3623
39. Battivelli E, Migraine J, Lecossier D, et al. Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity. J Virol 2011; 85: 11846-11854
40. Granier C, Battivelli E, Lecuroux C, et al. Pressure from TRIM5a contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles. J Virol 2013; 87: 10368-10380
41. Nepveu-Traversy ME, Berthoux L. The conserved sumoylation consensus site in TRIM5a modulates its immune activation functions. Virus Res 2014; 184: 30-38
42. Tareen SU, Emerman M. Human Trim5a has additional activities that are uncoupled from retroviral capsid recognition. Virology 2011; 409: 113-120
43. Sebastian S, Sokolskaja E, Luban J. Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner. J Virol 2006; 80: 2051-2054
44. Van Parijs L, Refaeli Y, Lord JD, et al. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 1999; 11: 281-288
45. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59: 284-291
46. Battivelli E, Lecossier D, Matsuoka S, et al. Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol 2010; 84: 11010-11019
47. Zennou V, Petit C, Guetard D, et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000; 101: 173-185
48. Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875
49. Li MJ, Bauer G, Michienzi A, et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 2003; 8: 196-206
50. Du G, Yonekubo J, Zeng Y, et al. Design of expression vectors for RNA interference based on miRNAs and RNA splicing. FEBS J 2006; 273: 5421-5427
51. Donnelly ML, Hughes LE, Luke G, et al. The cleavage activities of foot-And-mouth disease virus 2A site-directed mutants and naturally occurring 2A-like sequences. J Gen Virol 2001; 82: 1027-1041
52. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003; 77: 8957-8961
53. Trkola A, Matthews J, Gordon C, et al. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 1999; 73: 8966-8974
54. Bérubé J, Bouchard A, Berthoux L. Both TRIM5alpha and TRIMCyp have only weak antiviral activity in canine D17 cells. Retrovirology 2007; 4: 68
55. Kimpton J, Emerman M. Detection of replicationcompetent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992; 66: 2232-2239
56. Godbey WT, Zhang X, Chang F. The importance of and a method for including transfection efficiency into real-Time PCR data analyses. Biotechnol Bioeng 2008; 100: 765-772
57. Pacheco B, Finzi A, Stremlau M, et al. Adaptation of HIV-1 to cells expressing rhesus monkey TRIM5a. Virology 2010; 408: 204-212
58. Soll SJ, Wilson SJ, Kutluay SB, et al. Assisted evolution enables HIV-1 to overcome a high TRIM5a-imposed genetic barrier to rhesus macaque tropism. PLoS Pathog 2013; 9: e1003667
59. Qian J, Bours V, Manischewitz J, et al. Chemically selected subclones of the CEM cell line demonstrate resistance to HIV-1 infection resulting from a selective loss of NF-kappa B DNA binding proteins. J Immunol 1994; 152: 4183-4191
60. Uchil PD, Hinz A, Siegel S, et al. TRIM proteinmediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J Virol 2013; 87: 257-272
61. Corish P, Tyler-Smith C. Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng 1999; 12: 1035-1040
62. Diaz-Griffero F, Kar A, Perron M, et al. Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5alpha B-box 2 domain. J Virol 2007; 81: 10362-10378
63. Richardson MW, Guo L, Xin F, et al. Stabilized human TRIM5a protects human T cells from HIV-1 infection. Mol Ther 2014; 22: 1084-1095
64. Galao RP, Le Tortorec A, Pickering S, et al. Innate sensing of HIV-1 assembly by tetherin induces NFjB-dependent proinflammatory responses. Cell Host Microbe 2012; 12: 633-644
65. Tokarev A, Suarez M, Kwan W, et al. Stimulation of NF-jB activity by the HIV restriction factor BST2. J Virol 2013; 87: 2046-2057
66. Hofer-Warbinek R, Schmid JA, Stehlik C, et al. Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem 2000; 275: 22064-22068
67. Wang C, Deng L, Hong M, et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001; 412: 346-351
68. Chen ZJ. Ubiquitination in signaling to and activation of IKK. Immunol Rev 2012; 246: 95-106
69. Gu M, Ouyang C, Lin W, et al. Phosphatase holoenzyme PP1/GADD34 negatively regulates TLR response by inhibiting TAK1 serine 412 phosphorylation. J Immunol 2014; 192: 2846-2856
70. Kobayashi Y, Mizoguchi T, Take I, et al. Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase Adependent phosphorylation of TAK1. J Biol Chem 2005; 280: 11395-11403
71. Scott ML, Fujita T, Liou HC, et al. The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Genes Dev 1993; 7: 1266-1276
72. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006; 210: 171-186
73. Tian B, Nowak DE, Brasier AR. A TNF-induced gene expression program under oscillatory NFkappaB control. BMC Genomics 2005; 6: 137
74. Pahl HL. Activators and target genes of Rel/NFkappaB transcription factors. Oncogene 1999; 18: 6853-6866
75. Hoffmann A, Levchenko A, Scott ML, et al. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 2002; 298: 1241-1245
76. Werner SL, Kearns JD, Zadorozhnaya V, et al. Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20. Genes Dev 2008; 22: 2093-2101
77. Saccani S, Pantano S, Natoli G. Two waves of nuclear factor kappaB recruitment to target promoters. J Exp Med 2001; 193: 1351-1359
78. Rossetti M, Gregori S, Hauben E, et al. HIV-1-derived lentiviral vectors directly activate plasmacytoid dendritic cells, which in turn induce the maturation of myeloid dendritic cells. Hum Gene Ther 2011; 22: 177-188
79. Fujioka S, Niu J, Schmidt C, et al. NF-kappaB and AP-1 connection: mechanism of NF-kappaBdependent regulation of AP-1 activity. Mol Cell Biol 2004; 24: 7806-7819
80. Heyninck K, De Valck D, Vanden Berghe W, et al. The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP-or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell Biol 1999; 145: 1471-1482
81. Schutte J, Viallet J, Nau M, et al. jun-B inhibits and c-fos stimulates the transforming and transactivating activities of c-jun. Cell 1989; 59: 987-997
82. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20: 2390-2400
83. Popovic M, Sarngadharan MG, Read E, et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224: 497-500
84. Hutter G, Nowak D, Mossner M, et al. Long-Term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360: 692-698
85. Wilen CB, Wang J, Tilton JC, et al. Engineering HIV-resistant human CD4 + T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 2011; 7: e1002020
86. Vagima Y, Lapid K, Kollet O, et al. Pathways implicated in stem cell migration: the SDF-1/CXCR4 axis. Methods Mol Biol 2011; 750: 277-289
87. Anderson J, Li MJ, Palmer B, et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, tat-rev siRNA, and TAR decoy-in SCID-hu mouse-derived T cells. Mol Ther 2007; 15: 1182-1188
88. Ter Brake O, Berkhout B. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions. J Gene Med 2007; 9: 743-750
89. Boden D, Pusch O, Lee F, et al. Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003; 77: 11531-11535
90. Berkhout B, Das AT. HIV-1 escape from RNAi antivirals: yet another Houdini action? Mol Ther Nucleic Acids 2012; 1: e26
91. Eckert DM, Malashkevich VN, Hong LH, et al. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999; 99: 103-115
92. Egelhofer M, Brandenburg G, Martinius H, et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 2004; 78: 568-575
93. Hermann FG, Egerer L, Brauer F, et al. Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membraneanchored C-peptide maC46. J Virol 2009; 83: 4844-4853
94. Yu X, Lu L, Cai L, et al. Mutations of Gln64 in the HIV-1 gp41 N-Terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. J Virol 2012; 86: 589-593
95. Cullen BR. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 2006; 80: 1067-1076
96. Mariani R, Chen D, Schrofelbauer B, et al. Species-specific exclusion of APOBEC3g from HIV-1 virions by Vif. Cell 2003; 114: 21-31
97. Kirmaier A, Wu F, Newman RM, et al. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 2010; 8: e1000462
98. Hatziioannou T, Cowan S, Bieniasz PD. Capsiddependent and-independent postentry restrict tion of primate lentivirus tropism in rodent cells. J Virol 2004; 78: 1006-1011
99. Stremlau M, Perron M, Welikala S, et al. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 2005; 79: 3139-3145
100. Maillard PV, Reynard S, Serhan F, et al. Interfering residues narrow the spectrum of MLV restriction by human TRIM5alpha. PLoS Pathog 2007; 3: e200
101. Berthoux L, Sebastian S, Sokolskaja E, et al. Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in OldWorld monkey cells. Proc Natl Acad Sci USA 2005; 102: 14849-14853
102. Keckesova Z, Ylinen LM, Towers GJ. Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol 2006; 80: 4683-4690
103. Stremlau M, Song B, Javanbakht H, et al. Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. Virology 2006; 351: 112-120
104. Orzalli MH, Conwell SE, Berrios C, et al. Nuclear interferon-inducible protein 16 promotes silencing of herpesviral and transfected DNA. Proc Natl Acad Sci USA 2013; 110: E4492-E4501
105. Caposio P, Gugliesi F, Zannetti C, et al. A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cells. J Biol Chem 2007; 282: 33515-33529
106. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 157: 1262-1278
107. Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014; 32: 551-553